Evidence map›Paper›PMID 40066042›Full record

ArticleHeliyon2025

Characterization of the immune cell infiltration patterns in lung adenocarcinoma to facilitate immunotherapy.

Haili Li, Zanmei Qin, Xuemei Huang, Zuyou Wei, JingMin Deng

Abstract read
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haili LiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zanmei QinDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xuemei HuangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zuyou WeiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
JingMin DengDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although Immunotherapy has emerged as an efficient treatment in lung carcinoma, merely a subset of lung adenocarcinoma (LUAD) patients could be benefited from it. Increasing evidence revealed that tumor immune cell infiltrating (ICI) in the tumor microenvironment (TME) is highly related to patient prognosis and characteristics of the tumor. Thus far, the immune cell infiltration patterns of LUAD remain unclear. Herein, ESTIMATE and CIBERSORT algorithms were conducted to characterize the ICI patterns of 1155 patients with LUAD. Three ICI subtypes were determined, and the ICI score was constructed by performing PCA. A high ICI score group referred to increased activation of the signaling pathways related to immune activation and drug metabolism, reduced tumor mutation burden (TMB), as well as significantly higher expression levels of CTLA-4, PD-1, LAG3, and immune-activation-related genes. Patients who had high ICI scores showed better overall survival (OS) compared to those with low ICI scores, irrespective of TMB status. This study demonstrated that ICI scores serve as an original and effective indicator for independent prognostic prediction as well as customized immune therapy of LUAD. Establishing the ICI patterns of a larger patient population will extend our knowledg of TME, and it may facilitate the development of immunotherapies specific to LUAD.

Indexed as

Immune cell infiltrationImmunotherapyLung adenocarcinomaTumor microenvironment

Identifiers

PMID40066042
PMCPMC11891687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.